Arkolith/Insider Trading/KALV/Form 4

Palleiko Benjamin L

CHIEF EXECUTIVE OFFICER, DirectorKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed Jun 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
18
1 non-derivative · 17 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)480K—$00

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)47K——0
Jun 11, 2026Disposed to issuer(D)30K——0
Jun 11, 2026Disposed to issuer(D)34K——0
Jun 11, 2026Disposed to issuer(D)72K——0
Jun 11, 2026Disposed to issuer(D)53K——0
Jun 11, 2026Disposed to issuer(D)34K——0
Jun 11, 2026Disposed to issuer(D)75K——0
Jun 11, 2026Disposed to issuer(D)85K——0
Jun 11, 2026Disposed to issuer(D)38K——0
Jun 11, 2026Disposed to issuer(D)20K——0
Jun 11, 2026Disposed to issuer(D)26K——0
Jun 11, 2026Disposed to issuer(D)40K——0
Jun 11, 2026Disposed to issuer(D)114K——0
Jun 11, 2026Disposed to issuer(D)125K——0
Jun 11, 2026Disposed to issuer(D)256K——0
Jun 11, 2026Disposed to issuer(D)93K——0
Jun 11, 2026Disposed to issuer(D)305K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001366244-26-000012) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML